Abstract 305P
Background
Transition of HER2 status after neoadjuvant chemotherapy (NAC) has frequently been reported previously; however, few study has focused on HER2-low breast cancer. Here, we evaluated the HER2 transition proportion among HER2-zero and HER2-low breast cancer cases post-NAC and the impact of clinical outcome after our initial report on pathologic complete response, long term outcomes and recurrence pattern in between two groups after neoadjuvant chemotherapy (S Kang, European Journal of Cancer, 2022).
Methods
We retrospectively reviewed HER2-zero and HER2-low breast cancer patients who underwent NAC and surgical resection during 2014–2018 at Asan Medical Center. We included 1288 patients who had paired pre- and post-therapeutic HER2 status results. HER2-zero was defined as immunohistochemistry (IHC)0, and HER2-low was defined as IHC1+ or IHC2+, with in situ hybridization-negativity.
Results
Of patients who were HER2-zero pre-NAC(n=650), 68% and 29% of patients were HER2-zero and HER2-low, respectively, post-NAC. Among patients who were HER2-low pre-NAC(n=638), 32% of patients showed HER2 changes, and 59% of patients had a constant HER2-low status post-NAC. Patients with constant HER2-low or transitions from HER2-low to zero had a higher proportion of hormone-receptor [HR] positivity (84% and 79%) than those with changes from HER2-zero to low (77%) or with constant HER2-zero (56%), respectively. Multivariable logistic regression analysis revealed that patients with HR positivity had a higher probability of gaining HER2-low expression than those with HR negativity (Odds ratio 2.48). No significant differences were observed in terms of overall survival and disease-free survival between patients with and without HER2-changes according to hormone receptor status, except in the post-therapeutic HER2-low HR-negative subset.
Conclusions
Temporal heterogeneity of HER2-low expression is observed in substantial portions of post-NAC breast cancer patients. Clinical outcomes show no significant associations, except in the post-therapeutic HER2-low, HR-negative subset. Prognostic implications of HER2 transition in HER2-low breast cancer require further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K.H. Jung: Non-Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Celgene, Eisai, Takeda, Novartis, Everest Medicine, Merck, Bixink. S. Kim: Non-Financial Interests, Institutional, Advisory Board: Lilly; Non-Financial Interests, Personal, Advisory Board: AstraZeneca, Daehwa Pharmaceutical, ISU Abxis, BeiGene, Daiichi Sankyo/AstraZeneca, OBI Pharma; Financial Interests, Personal, Stocks/Shares: Neogene Therapeutics, TC Corp, Genopeaks; Financial Interests, Personal, Other, Honoria: Daehwa Pharmaceutical, LegoChem Biosciences, Kalbe; Financial Interests, Institutional, Research Grant: Novartis, Dongkook Pharma, Genzyme. All other authors have declared no conflicts of interest.
Resources from the same session
252P - Adjuvant chemotherapy in T1a/bN0 breast cancer patients with high oncotype DX recurrence scores (RS>25)
Presenter: Daniela Katz
Session: Poster session 02
253P - Is 6-weekly administration of pembrolizumab in combination with chemotherapy for early triple-negative breast cancer safe? A real-world early comparison of q6w versus q3w administration of pembrolizumab in two large cancer centres in the UK
Presenter: Vasileios Angelis
Session: Poster session 02
254P - Effects of delaying adjuvant chemotherapy initiation on clinical outcomes in early triple-negative breast cancer patients
Presenter: Maria Eleni Hatzipanagiotou
Session: Poster session 02
255P - Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Presenter: Nicolas Roussot
Session: Poster session 02
256P - Evolution and risk stratification of adjuvant treatment strategies for early breast cancer: A Chinese perspective based on a national cancer database
Presenter: Ying Fan
Session: Poster session 02
257P - The characteristics of HER2-positive microinvasive breast cancer and the necessity of chemotherapy and anti-HER2 therapy in these patients: A real-world study
Presenter: Bo Lan
Session: Poster session 02
258P - Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia
Presenter: Ricardo Brugés Maya
Session: Poster session 02
259P - Adjuvant doxorubicin-cyclophosphamide in early-stage breast cancer provides long-term cardiac safety
Presenter: Thiti Susiriwatananont
Session: Poster session 02
260P - Oncology efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
Presenter: Hee Jun Choi
Session: Poster session 02
261P - Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients undergoing neoadjuvant chemotherapy: A comparison between TNBC and non-TNBC patients
Presenter: Bernardo Rapoport
Session: Poster session 02